Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 CAD | +1.34% | +0.27% | -4.56% |
Business Summary
Number of employees: 91
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 80 | 100.0 % | 85 | 100.0 % | +6.38% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
62.3
%
| 48 | 60.2 % | 53 | 62.3 % | +10.03% |
United States
29.3
%
| 25 | 31.8 % | 25 | 29.3 % | -2.12% |
Rest of World
8.4
%
| 6 | 7.9 % | 7 | 8.4 % | +12.78% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 23-04-30 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Ryan Lennox
CMP | Compliance Officer | 43 | 18-05-06 |
Jason Gross
CTO | Chief Tech/Sci/R&D Officer | 59 | 14-05-31 |
Brian Walsh
PRN | Corporate Officer/Principal | - | 23-05-31 |
Patricia Perry
HRO | Human Resources Officer | 48 | 19-06-30 |
David Spence
AUD | Comptroller/Controller/Auditor | 56 | 17-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Welborn
CHM | Chairman | 46 | 21-06-17 |
Laura Brege
BRD | Director/Board Member | 66 | 19-03-20 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Craig Millian
CEO | Chief Executive Officer | 56 | 23-04-30 |
Rodney Hill
BRD | Director/Board Member | 56 | 18-03-11 |
Norma Beauchamp
BRD | Director/Board Member | 62 | 20-12-31 |
Kyle Dempsey
BRD | Director/Board Member | 35 | 22-11-28 |
Christian Roy
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 31,886,247 | 31,771,782 ( 99.64 %) | 0 | 99.64 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.56% | 86.87M | |
+23.99% | 74.5B | |
-2.21% | 24.24B | |
+10.52% | 8.45B | |
+4.65% | 8.44B | |
-21.71% | 7.65B | |
+11.90% | 5.24B | |
+2.27% | 4.14B | |
-4.23% | 3.95B | |
+5.42% | 3.83B |
- Stock Market
- Equities
- HLS Stock
- Company HLS Therapeutics Inc.